To identify what cell types and TME signaling pathways might contribute to resistance to ICI treatment, we obtained bulk RNA-seq data from a recent gastric cancer study [6] that evaluated gene expression in tumor samples from 45 patients treated with anti-PD-1 (pembrolizumab) therapy. This evidence concerns the gene PDCD1 and neoplasm.